Clinical Trial: Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07694297) titled 'Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure' on July 03.

Brief Summary: Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Acute Decompensation of Liver Cirrhosis Established Acute-on-Chronic Liver Failure

Intervent...